Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort-Reference-Cited by-同舟云学术

Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort

Published:2023-11-06 Issue: Volume: Page:1-9
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Iborra Marisa¹,Ferreiro-Iglesias Rocio²,Maria Dolores Martín-Arranz³,Mesonero Gismero Francisco⁴,Mínguez Alejandro¹,Porto-Silva Sol²,García-Ramírez Laura⁵,García de la Filia Irene⁴,Aguas Mariam¹,Nieto-García Laura²,Suárez Ferrer Cristina³,Bastida Guillermo¹,Barreiro-De-Acosta Manuel²,Nos Pilar¹

Affiliation:

1. Inflammatory Bowel Disease Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

2. Gastroenterology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain

3. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain

4. Gastroenterology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain

5. Fundación para la Investigación Biomédica, Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ, Madrid, Spain

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2023.2278427

Reference40 articles.

1. Ulcerative colitis

2. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

3. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

4. Stelara Summary of Product Characteristics. [cited 2023 Jun 20]. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.

5. Re-induction With Intravenous Ustekinumab in Patients With Crohn’s Disease and a Loss of Response to This Therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments;Trends in Pharmacological Sciences;2024-09

2. Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan;Biomedicines;2024-05-17

3. Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center;Journal of Gastroenterology and Hepatology;2024-04-28

4. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms;Journal of Clinical Medicine;2024-03-06

5. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study;Expert Opinion on Biological Therapy;2024-01-25